Please provide your email address to receive an email when new articles are posted on . Ocrelizumab reduced the number and size of MS-related cortical lesions. Data synthesis featuring a mix of ...
The second substudy involved 38 patients who switched from ocrelizumab (Ocrevus, Genentech), 22 of whom experienced wearing-off effects that prompted the switch after three to five rounds of ...
Your Privacy is Important To Us. Buffalo.edu uses cookies to help build a better website experience for our visitors. Learn more in our Privacy Policy.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback